Fig. 4. (A) RNA expression profile of downregulated ECM genes in skin of untreated (0d) and treated (1d and 4d) transgenic and wild-type mice. (B) Immunolabelling of 4 days treated skin with antibodies to the proteins indicated. (C) Western blotting with anti-fibronectin antibody (upper panel) of wild-type (wt) and transgenic (tg) mice skin untreated (0d) or treated with OHT for 1 day or 4 days (1d, 4d). Actin was used as a loading control (lower panel). (D) Relative PCR determination of fibronectin mRNA levels in skin of wild-type (wt) and transgenic (tg) animals treated with OHT for 4 days (4d) (P=0.055). (E) Western blotting with anti-fibronectin antibody (upper panel) and anti-actin antibody as control (lower panel). Primary human keratinocytes overexpressing Myc (Kq-MycER) are compared to controls (Kq-106ER, Kq-pBP). (F) Immunolabelling of fibronectin and laminin at the wound margins of skin from wild-type and transgenic mice that had been wounded and then treated with OHT for 4 days. Skin was harvested after the number of days shown. Arrowheads indicate the expression of fibronectin and laminin at the basement membrane zone. Scale bar: 10 µm.

Return to article